Denali Therapeutics (DNLI) Change in Accured Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has reported Change in Accured Expenses for 10 consecutive years, with -$22.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 131.21% year-over-year to -$22.4 million; the TTM figure through Mar 2026 stood at -$12.2 million (down 39.79% YoY), while the FY2025 annual figure was $465000.0, down 85.68% from the prior year.
• Change in Accured Expenses fell to -$22.4 million in Q1 2026 per DNLI's latest filing, from $12.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $24.6 million in Q3 2024 and bottomed at -$32.2 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged -$300941.2 across 5 years, with a median of $1.9 million in 2025.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 649.17% — and 2024, when it soared 3249.59%.
• Denali Therapeutics' Change in Accured Expenses stood at $4.0 million in 2022, then jumped by 255.43% to $14.3 million in 2023, then slumped by 119.86% to -$2.8 million in 2024, then surged by 547.82% to $12.7 million in 2025, then sank by 275.96% to -$22.4 million in 2026.
• Business Quant data shows DNLI's Change in Accured Expenses at -$22.4 million in Q1 2026, $12.7 million in Q4 2025, and $1.9 million in Q3 2025.